Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Study Details
Study Description
Brief Summary
This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the body (metastatic) and have come back (recurrent) or do not respond to treatment (refractory). Samotolisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Detailed Description
PRIMARY OBJECTIVE:
- To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with samotolisib (LY3023414) with advanced solid tumors, non-Hodgkin lymphomas or central nervous system (CNS) tumors that harbor TSC loss of function mutations, and/or other PI3K/MTOR activating mutations.
SECONDARY OBJECTIVES:
-
To estimate the progression free survival in pediatric patients treated with LY3023414 with advanced solid tumors, non-Hodgkin lymphomas or CNS tumors that harbor TSC loss of function mutations, and/or other PI3K/MTOR activating mutations.
-
To obtain information about the tolerability of LY3023414 in children with relapsed or refractory cancer.
-
To characterize the pharmacokinetics of LY3023414 in children with recurrent or refractory cancer.
EXPLORATORY OBJECTIVES:
-
To increase knowledge of the genomic landscape of relapsed pediatric solid tumors and lymphomas and identify potential predictive biomarkers (other than the genomic alteration for which study treatment was assigned) using additional genomic, transcriptomic, and proteomic testing platforms.
-
To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA).
-
To evaluate the frequency and mechanism of biallelic loss of function, and evaluate the expression of TSC1, TSC2, and PTEN in subjects who enroll with a loss of function mutation in one of these genes.
OUTLINE: This is a dose-escalation study.
Patients receive samotolisib orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed up periodically.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Treatment (samotolisib) Patients receive samotolisib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity. |
Other: Laboratory Biomarker Analysis
Correlative studies
Other: Pharmacological Study
Correlative studies
Drug: Samotolisib
Given PO
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Response rate [Up to 2 years]
Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method.
Secondary Outcome Measures
- Percentage of patients experiencing grade 3 or 4 adverse events [From enrollment to the end of treatment, up to 2 years]
Will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Any eligible patient who receives at least one dose of protocol therapy will be considered in the evaluation of toxicity.
- Progression free survival (PFS) [From the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause, assessed up to 2 years]
PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.
- Pharmacokinetic (PK) parameters [At baseline, 30 minutes, 1, 2, 4, 4, 6-8 hours, and 24 hours after the morning dose on day 1 course 1, pre-dose and at 1-2 hours after the morning dose on day 15 course 1]
A descriptive analysis of pharmacokinetic (PK) parameters will be performed to define systemic exposure, drug clearance, and other pharmacokinetic parameters. The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).
Other Outcome Measures
- Potential predictive biomarker identification using additional genomic, transcriptomic, and proteomic testing platforms [Up to 3 years]
A descriptive analysis will be performed and will be summarized with simple summary statistics. All of these analyses will be descriptive in nature.
- Biallelic loss of function frequency and mechanism [Up to 3 years]
A descriptive analysis will be performed and will be summarized with simple summary statistics. All of these analyses will be descriptive in nature.
- Change in tumor genomic profile [Baseline up to 3 years]
A descriptive analysis will be performed and will be summarized with simple summary statistics. All of these analyses will be descriptive in nature.
- TSC1, TSC2, and PTEN expression levels [Up to 3 years]
A descriptive analysis will be performed and will be summarized with simple summary statistics. All of these analyses will be descriptive in nature.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APEC1621D based on the presence of an actionable mutation as defined in APEC1621SC; note that treatment assignment may be to primary cohort A for patients with TSC1 or TSC2 loss of function mutations or primary cohort B for patients with other PI3K/MTOR pathway mutations
-
Patients accruing to dose level 1 must have a body surface area >= 0.52 m2 at the time of study enrollment; patients accruing to dose level 2 must have a body surface area >= 0.37 m2 at the time of study enrollment; patients accruing to dose level -1 must have a body surface area >= 0.75 m^2 at the time of study enrollment
-
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard magnetic resonance imaging (MRI) or computed tomography (CT)
-
Note: The following do not qualify as measurable disease:
-
Malignant fluid collections (e.g., ascites, pleural effusions)
-
Bone marrow infiltration except that detected by MIBG scan for neuroblastoma
-
Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma
-
Elevated tumor markers in plasma or cerebrospinal fluid (CSF)
-
Previously radiated lesions that have not demonstrated clear progression post radiation
-
Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
-
Bone lesions without an associated soft tissue mass >= 10 mm in greatest diameter; bone lesions with an associated soft tissue mass >= 10 mm in greatest diameter imaged by CT or MRI are considered measurable
-
Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; Note: neurologic deficits in patients with CNS tumors must have been stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
-
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
-
Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive;
= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
-
Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent
-
Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
-
Corticosteroids: if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
-
Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator
-
Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)
-
Stem cell Infusions (with or without total body irradiation [TBI]):
-
Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion:
= 84 days after infusion and no evidence of graft versus host disease (GVHD)
-
Autologous stem cell infusion including boost infusion: >= 42 days
-
Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)
-
Radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation
-
Note: radiation may not be delivered to "measurable disease" tumor site(s) being used to follow response to subprotocol treatment
-
Radiopharmaceutical therapy (e.g., radiolabeled antibody, iobenguane I-131 [131I-MIBG]): >= 42 days after systemically administered radiopharmaceutical therapy
-
Patients must not have received prior exposure to LY3023414
-
Patients must not have received prior exposure to an agent specifically directed at the PI3K/MTOR pathway (a PI3K inhibitor, an AKT inhibitor, an MTOR inhibitor, including rapalogs, or a combined PI3K/MTOR inhibitor)
-
For patients with solid tumors without known bone marrow involvement:
-
Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
-
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
-
Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:
-
Age: 1 to < 2 years; maximum serum creatinine (mg/dL): male 0.6; female 0.6
-
Age: 2 to < 6 years; maximum serum creatinine (mg/dL): male 0.8; female 0.8
-
Age: 6 to < 10 years; maximum serum creatinine (mg/dL): male 1; female 1
-
Age: 10 to < 13 years; maximum serum creatinine (mg/dL): male 1.2; female 1.2
-
Age: 13 to < 16 years; maximum serum creatinine (mg/dL): male 1.5; female 1.4
-
Age: >= 16 years; maximum serum creatinine (mg/dL): male 1.7; female 1.4
-
Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
-
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L; (for the purpose of this study, the ULN for SGPT is 45 U/L)
-
Serum albumin >= 2 g/dL
-
Patients must have a normal blood sugar level for age; if an initial random draw (i.e. non-fasting) blood glucose value is out of range, it is acceptable to repeat this test as a fasting draw
-
Patients must have a serum triglyceride level =< 300 mg/dL and serum cholesterol level =< 300 mg/dL; if an initial random draw (i.e. non-fasting) is out of range, it is acceptable to repeat this test as a fasting draw
-
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
-
Nervous system disorders (by Common Terminology Criteria for Adverse Events version 5.0 [CTCAE V 5.0]) resulting from prior therapy must be =< grade 2, with the exception of decreased tendon reflex (DTR); any grade of DTR is eligible
-
Corrected QT (QTc) interval =< 480 milliseconds
-
Patients must be able to swallow intact tablets
-
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
Exclusion Criteria:
-
Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while receiving study treatment and for 3 months after the last dose of LY3023414
-
Concomitant medications
-
Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy,
= 14 days must have elapsed since last dose of corticosteroid
-
Investigational drugs: patients who are currently receiving another investigational drug are not eligible
-
Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible
-
Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
-
Patients who have an uncontrolled infection are not eligible
-
Patients who have insulin dependent diabetes are not eligible
-
Patients who have received a prior solid organ transplantation are not eligible
-
Patients with subependymal giant cell astrocytomas (SEGAs) are not eligible
-
Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Children's Hospital of Alabama | Birmingham | Alabama | United States | 35233 |
2 | Providence Alaska Medical Center | Anchorage | Alaska | United States | 99508 |
3 | Banner Children's at Desert | Mesa | Arizona | United States | 85202 |
4 | Banner University Medical Center - Tucson | Tucson | Arizona | United States | 85719 |
5 | Arkansas Children's Hospital | Little Rock | Arkansas | United States | 72202-3591 |
6 | Kaiser Permanente Downey Medical Center | Downey | California | United States | 90242 |
7 | City of Hope Comprehensive Cancer Center | Duarte | California | United States | 91010 |
8 | Loma Linda University Medical Center | Loma Linda | California | United States | 92354 |
9 | Miller Children's and Women's Hospital Long Beach | Long Beach | California | United States | 90806 |
10 | Children's Hospital Los Angeles | Los Angeles | California | United States | 90027 |
11 | Mattel Children's Hospital UCLA | Los Angeles | California | United States | 90095 |
12 | Valley Children's Hospital | Madera | California | United States | 93636 |
13 | UCSF Benioff Children's Hospital Oakland | Oakland | California | United States | 94609 |
14 | Kaiser Permanente-Oakland | Oakland | California | United States | 94611 |
15 | University of California Davis Comprehensive Cancer Center | Sacramento | California | United States | 95817 |
16 | UCSF Medical Center-Mission Bay | San Francisco | California | United States | 94158 |
17 | Children's Hospital Colorado | Aurora | Colorado | United States | 80045 |
18 | Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center | Denver | Colorado | United States | 80218 |
19 | Yale University | New Haven | Connecticut | United States | 06520 |
20 | Alfred I duPont Hospital for Children | Wilmington | Delaware | United States | 19803 |
21 | MedStar Georgetown University Hospital | Washington | District of Columbia | United States | 20007 |
22 | Children's National Medical Center | Washington | District of Columbia | United States | 20010 |
23 | University of Florida Health Science Center - Gainesville | Gainesville | Florida | United States | 32610 |
24 | Nemours Children's Clinic-Jacksonville | Jacksonville | Florida | United States | 32207 |
25 | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami | Florida | United States | 33136 |
26 | Nicklaus Children's Hospital | Miami | Florida | United States | 33155 |
27 | AdventHealth Orlando | Orlando | Florida | United States | 32803 |
28 | Arnold Palmer Hospital for Children | Orlando | Florida | United States | 32806 |
29 | Nemours Children's Hospital | Orlando | Florida | United States | 32827 |
30 | Nemours Children's Clinic - Pensacola | Pensacola | Florida | United States | 32504 |
31 | Johns Hopkins All Children's Hospital | Saint Petersburg | Florida | United States | 33701 |
32 | Saint Joseph's Hospital/Children's Hospital-Tampa | Tampa | Florida | United States | 33607 |
33 | Children's Healthcare of Atlanta - Egleston | Atlanta | Georgia | United States | 30322 |
34 | Memorial Health University Medical Center | Savannah | Georgia | United States | 31404 |
35 | Saint Luke's Cancer Institute - Boise | Boise | Idaho | United States | 83712 |
36 | University of Chicago Comprehensive Cancer Center | Chicago | Illinois | United States | 60637 |
37 | Saint Jude Midwest Affiliate | Peoria | Illinois | United States | 61637 |
38 | Southern Illinois University School of Medicine | Springfield | Illinois | United States | 62702 |
39 | Riley Hospital for Children | Indianapolis | Indiana | United States | 46202 |
40 | Blank Children's Hospital | Des Moines | Iowa | United States | 50309 |
41 | University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa | United States | 52242 |
42 | Norton Children's Hospital | Louisville | Kentucky | United States | 40202 |
43 | Children's Hospital New Orleans | New Orleans | Louisiana | United States | 70118 |
44 | Ochsner Medical Center Jefferson | New Orleans | Louisiana | United States | 70121 |
45 | Eastern Maine Medical Center | Bangor | Maine | United States | 04401 |
46 | Sinai Hospital of Baltimore | Baltimore | Maryland | United States | 21215 |
47 | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | United States | 21287 |
48 | Massachusetts General Hospital Cancer Center | Boston | Massachusetts | United States | 02114 |
49 | Dana-Farber Cancer Institute | Boston | Massachusetts | United States | 02215 |
50 | C S Mott Children's Hospital | Ann Arbor | Michigan | United States | 48109 |
51 | Michigan State University Clinical Center | East Lansing | Michigan | United States | 48824-7016 |
52 | Helen DeVos Children's Hospital at Spectrum Health | Grand Rapids | Michigan | United States | 49503 |
53 | Bronson Methodist Hospital | Kalamazoo | Michigan | United States | 49007 |
54 | Children's Hospitals and Clinics of Minnesota - Minneapolis | Minneapolis | Minnesota | United States | 55404 |
55 | University of Minnesota/Masonic Cancer Center | Minneapolis | Minnesota | United States | 55455 |
56 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
57 | University of Mississippi Medical Center | Jackson | Mississippi | United States | 39216 |
58 | Children's Mercy Hospitals and Clinics | Kansas City | Missouri | United States | 64108 |
59 | Cardinal Glennon Children's Medical Center | Saint Louis | Missouri | United States | 63104 |
60 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
61 | Mercy Hospital Saint Louis | Saint Louis | Missouri | United States | 63141 |
62 | Children's Hospital and Medical Center of Omaha | Omaha | Nebraska | United States | 68114 |
63 | University of Nebraska Medical Center | Omaha | Nebraska | United States | 68198 |
64 | University Medical Center of Southern Nevada | Las Vegas | Nevada | United States | 89102 |
65 | Sunrise Hospital and Medical Center | Las Vegas | Nevada | United States | 89109 |
66 | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas | Nevada | United States | 89135 |
67 | Summerlin Hospital Medical Center | Las Vegas | Nevada | United States | 89144 |
68 | Hackensack University Medical Center | Hackensack | New Jersey | United States | 07601 |
69 | Morristown Medical Center | Morristown | New Jersey | United States | 07960 |
70 | Saint Peter's University Hospital | New Brunswick | New Jersey | United States | 08901 |
71 | Albany Medical Center | Albany | New York | United States | 12208 |
72 | Montefiore Medical Center - Moses Campus | Bronx | New York | United States | 10467 |
73 | Roswell Park Cancer Institute | Buffalo | New York | United States | 14263 |
74 | The Steven and Alexandra Cohen Children's Medical Center of New York | New Hyde Park | New York | United States | 11040 |
75 | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York | New York | United States | 10032 |
76 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10065 |
77 | NYP/Weill Cornell Medical Center | New York | New York | United States | 10065 |
78 | University of Rochester | Rochester | New York | United States | 14642 |
79 | State University of New York Upstate Medical University | Syracuse | New York | United States | 13210 |
80 | New York Medical College | Valhalla | New York | United States | 10595 |
81 | Mission Hospital | Asheville | North Carolina | United States | 28801 |
82 | Carolinas Medical Center/Levine Cancer Institute | Charlotte | North Carolina | United States | 28203 |
83 | Duke University Medical Center | Durham | North Carolina | United States | 27710 |
84 | Sanford Broadway Medical Center | Fargo | North Dakota | United States | 58122 |
85 | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | United States | 45229 |
86 | Rainbow Babies and Childrens Hospital | Cleveland | Ohio | United States | 44106 |
87 | Cleveland Clinic Foundation | Cleveland | Ohio | United States | 44195 |
88 | Nationwide Children's Hospital | Columbus | Ohio | United States | 43205 |
89 | Dayton Children's Hospital | Dayton | Ohio | United States | 45404 |
90 | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo | Ohio | United States | 43606 |
91 | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | United States | 73104 |
92 | Legacy Emanuel Children's Hospital | Portland | Oregon | United States | 97227 |
93 | Oregon Health and Science University | Portland | Oregon | United States | 97239 |
94 | Geisinger Medical Center | Danville | Pennsylvania | United States | 17822 |
95 | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States | 19104 |
96 | Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | United States | 15224 |
97 | Prisma Health Richland Hospital | Columbia | South Carolina | United States | 29203 |
98 | BI-LO Charities Children's Cancer Center | Greenville | South Carolina | United States | 29605 |
99 | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota | United States | 57117-5134 |
100 | East Tennessee Childrens Hospital | Knoxville | Tennessee | United States | 37916 |
101 | Saint Jude Children's Research Hospital | Memphis | Tennessee | United States | 38105 |
102 | Vanderbilt University/Ingram Cancer Center | Nashville | Tennessee | United States | 37232 |
103 | Dell Children's Medical Center of Central Texas | Austin | Texas | United States | 78723 |
104 | Medical City Dallas Hospital | Dallas | Texas | United States | 75230 |
105 | UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Texas | United States | 75390 |
106 | Cook Children's Medical Center | Fort Worth | Texas | United States | 76104 |
107 | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston | Texas | United States | 77030 |
108 | M D Anderson Cancer Center | Houston | Texas | United States | 77030 |
109 | Children's Hospital of San Antonio | San Antonio | Texas | United States | 78207 |
110 | Methodist Children's Hospital of South Texas | San Antonio | Texas | United States | 78229 |
111 | University of Texas Health Science Center at San Antonio | San Antonio | Texas | United States | 78229 |
112 | Scott and White Memorial Hospital | Temple | Texas | United States | 76508 |
113 | Primary Children's Hospital | Salt Lake City | Utah | United States | 84113 |
114 | University of Vermont and State Agricultural College | Burlington | Vermont | United States | 05405 |
115 | Children's Hospital of The King's Daughters | Norfolk | Virginia | United States | 23507 |
116 | Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia | United States | 23298 |
117 | Seattle Children's Hospital | Seattle | Washington | United States | 98105 |
118 | Providence Sacred Heart Medical Center and Children's Hospital | Spokane | Washington | United States | 99204 |
119 | Mary Bridge Children's Hospital and Health Center | Tacoma | Washington | United States | 98405 |
120 | Madigan Army Medical Center | Tacoma | Washington | United States | 98431 |
121 | West Virginia University Healthcare | Morgantown | West Virginia | United States | 26506 |
122 | University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | United States | 53792 |
123 | Children's Hospital of Wisconsin | Milwaukee | Wisconsin | United States | 53226 |
124 | San Jorge Children's Hospital | San Juan | Puerto Rico | 00912 | |
125 | University Pediatric Hospital | San Juan | Puerto Rico | 00926 |
Sponsors and Collaborators
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Theodore W Laetsch, Children's Oncology Group
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NCI-2017-01249
- NCI-2017-01249
- APEC1621D
- APEC1621D
- APEC1621D
- U10CA180886